Browsing Tag
ELVN-001
2 posts
Enliven Therapeutics appoints Kristine Ball as $895m-backed leukemia Phase 3 trial nears
Enliven Therapeutics has expanded its board and appointed a new audit committee member as it prepares to initiate a pivotal 450-patient study of relcobatinib before the end of 2026. With FDA alignment secured on the trial design and substantial cash reserves, attention is shifting towards clinical execution, competitive differentiation and eventual commercial readiness.
Why Enliven’s FDA alignment may matter as ELVN-001 moves toward Phase 3
Find out how Enliven’s ELVN-001 data and FDA alignment could reshape the next phase of chronic myeloid leukemia therapy.